Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately
The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.
Why all heart patients should be vaccinated against the flu, COVID-19, RSV
The American College of Cardiology has shared new recommendations highlighting the protective benefits of a variety of vaccines. The new guidance also examines how to speak with patients who are hesitant to be vaccinated.
First study of its kind to focus on new therapy for hypoplastic left heart syndrome
The new trial represents a potential breakthrough in the treatment of one of the most devastating congenital heart defects.
Real-world data link semaglutide, tirzepatide to improved heart failure outcomes
GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.
Beta blockers ‘have no effect’ on heart attack patients
One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

FDA announces another recall of common hypertension medication due to potential cancer risk

The new recall includes five lots of medications distributed from December 2019 to April 2022. Similar products were also recalled back in March for the same reason.

FDA announces new insulin recall due to potential labeling issue

The recall is focused on a single batch distributed from December 2021 to March 2022.

Steven Nissen, MD, Cleveland Clinic, explains an ACC.22 late-breaking trials that uses an mRNA drug to greatly reduce lipoprotein A. #ACC22

VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98%

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

Older LAAO patients, especially women, face a higher risk of complications

Researchers explored data from the National Inpatient Sample, sharing their findings in the American Journal of Cardiology.

DOACs an effective substitute for VKAs after AFib patients undergo bioprosthetic valve replacement

Direct oral anticoagulants are noninferior to vitamin K antagonists when treating this important patient population, researchers reported.

Evolocumab limits adverse cardiovascular outcomes among PCI patients

Data from the FOURIER trial helped clinicians learn more about this popular PCSK9 inhibitor.

USPSTF shares updated recommendations on statin use to prevent CVD

The public comment period for these recommendations ends on March 21.

Ticagrelor alone after DAPT lowers bleeding risk among heart attack patients undergoing PCI

Researchers examined data from the TWILIGHT study to track how different treatment strategies can impact 12-month PCI outcomes.

Pharmaceutics

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately

Why all heart patients should be vaccinated against the flu, COVID-19, RSV

First study of its kind to focus on new therapy for hypoplastic left heart syndrome

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

Beta blockers ‘have no effect’ on heart attack patients